Avalo Therapeutics Purchases Optional Milestone Buyout

Avalo Therapeutics entered into a Milestone Buyout Option Agreement to modify the terms of its prior acquisition of AlmataBio, effectively replacing a $15 million contingent milestone liability. Under the new terms, Avalo paid $2.25 million for a 90-day option to pay an additional $5.125 million in cash, stock, or a combination upon Phase 3 initiation, significantly reducing potential future cash outflows.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.